Nazanin Talebabadi

Ms. Nazanin Talebabadi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Hemato
Verified
Journal Article
Open access
PDF file
NTNazanin Talebabadi
Nazanin Talebabadi
ETEusni Rahayu Mohd. Tohit
Eusni Rahayu Mohd. Tohit
MAMaha Abdullah
Maha Abdullah
SSSiti Yazmin Zahari Sham
Siti Yazmin Zahari Sham
NZNur Fatin Zalikha Zailan
Nur Fatin Zalikha Zailan
MHMASRIANA HASSAN
MASRIANA HASSAN
Obesity is among the most prevalent risk factors in the severe forms of Coronavirus disease 2019 (COVID-19) infection. COVID-19 patients with obesity often face severe complications that might be associated with overexpression of adiponectin, inflammatory cytokines, and angiotensin-converting enzyme 2 (ACE2) receptors in visceral fat. The pre-existing subclinical inflammation associated with obesity can also lead to severe inflammatory responses. Elevation of proinflammatory cytokines considerably activates coagulation cascades, including the tissue factor (TF) pathway. The hypercoagulable state in COVID-19 is presented with severe pulmonary complications such as venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), and disruption of vascular endothelial cells, which can lead to severe complications and death. The interaction between inflammatory response and coagulation mechanism in COVID-19 patients with obesity warrants a further understanding of prognosis and potential therapeutic approaches. This review discusses the crosstalk between inflammation and coagulopathy in obesity-related severe COVID-19 infection.

14 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
NTNazanin Talebabadi
Nazanin Talebabadi
ETEusni Rahayu Mohd. Tohit
Eusni Rahayu Mohd. Tohit
MAMaha Abdullah
Maha Abdullah
SSSiti Yazmin Zahari Sham
Siti Yazmin Zahari Sham
NZNur Fatin Zalikha Zailan
Nur Fatin Zalikha Zailan
MHMASRIANA HASSAN
MASRIANA HASSAN
Obesity is among the most prevalent risk factors in the severe forms of Coronavirus disease 2019 (COVID-19) infection. COVID-19 patients with obesity often face severe complications that might be associated with overexpression of adiponectin, inflammatory cytokines, and angi-otensin-converting enzyme 2 (ACE2) receptors in visceral fat. The pre-existing subclinical in-flammation associated with obesity can also lead to severe inflammatory responses. Elevation of pro-inflammatory cytokines considerably activates coagulation cascades, including the tissue factor (TF) pathway. The hypercoagulable state in COVID-19 is presented by severe pulmonary complications such as venous thromboembolism (VTE), disseminated intravascular coagulation (DIC), and disruption of vascular endothelial cells which can lead to severe complications and death. The interaction between inflammatory response and coagulation mechanism in COVID-19 patients with obesity warrants a further understanding of prognosis and potential therapeutic approaches. This review discussed the crosstalk between inflammation and coagulopathy in obesity-related severe COVID-19 infection.